Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer

Sara M. Tolaney

Department of Medical Oncology, Dana-Farber Cancer Institute

Evandro de Azambuja

Institut Jules Bordet, Hôpital Universitaire de Bruxelles and Université Libre de Bruxelles, Brussels

Kevin Kalinsky

Winship Cancer Institute, Emory University, Atlanta

Sherene Loi

Sung-Bae Kim

Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

Clinton Yam

Bernardo Rapoport

Medical Oncology Centre of Rosebank, Clinical and Translational Research Unit, Saxonwold, South Africa

Seock-Ah Im

Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, South Korea

Barbara Pistilli

Department of Cancer Medicine, Gustave Roussy, Villejuif, France

Wassim Mchayleh

AdventHealth Cancer Institute, Orlando, FL

David W. Cescon

Princess Margaret Cancer Centre, University Health Network, Toronto

Junichiro Watanabe

Juntendo University Graduate School of Medicine, Tokyo

Manuel Alejandro Lara Bañuelas

SCIENTIA Investigación Clínica, Chihuahua, Mexico

Ruffo Freitas-Junior

Araujo Jorge Cancer Hospital, Goias Anticancer Association, Goiânia, Brazil

Javier Salvador Bofill

Medical Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain

Maryam Afshari

Gilead Sciences, Foster City, CA

Dianna Gary

Gilead Sciences, Foster City, CA

Lu Wang

Catherine Lai

Gilead Sciences, Foster City, CA

Peter Schmid

Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London